Caution advised on tamoxifen use

5 November 2001

An analysis published in the British Journal of Cancer (November 4) hassuggested that use of the mainstay breast cancer drug tamoxifen in the prevention of the disease in healthy women may be undermined by its significant side-effect burden. The researchers note that women over the age of 50 who received the drug had up to a four-fold greater risk of endometrial cancer and double the risk of deep vein thrombosis. They suggest that use of the drug in at-risk, healthy women may only be advised if their predicted risk is at least three times greater than average.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight